What companies has Blue Origin partnered with for space travel?

Blue Origin has announced partnerships with Lockheed Martin, Northrop Grumman, and Draper to advance their commercial space flight endeavors.

Which CEOs are stepping down from their positions?

The CEOs of Under Armour and Nike have announced that they will be resigning from their positions, effective January 2020.

What is Draper's role in the commercial space flight project?

Draper will collaborate with Blue Origin, Lockheed Martin, and Northrop Grumman to contribute their expertise in engineering and technology for the commercial space flight initiative.

‹ Back to Industries

Sciences

This Week’s 3 Big Things in B2B: A Big Day for Space Travel and CEOs

Geoff Short discusses major developments in the B2B world this week, including new business collaborations by Blue Origin with Lockheed Martin, Northrop Grumman, and Draper for commercial space flight. Additionally, top executives from Under Armour and Nike announced their departures.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

Promoted content from Draper on MarketScale.

By Geoff Short · October 24, 2019, 5:34 PM UTCBlue OriginHalloweenJeff BezosKevin Plank

Key takeaways

Blue Origin partners with Lockheed Martin, Northrop Grumman, and Draper.

Executives from Under Armour and Nike announced their departures.

Commercial space flight developments are progressing.

These are the biggest stories in the B2B world this week! In fact, one is out of this world! Blue Origin, Jeff Bezos’ company focused on bringing people to the moon, announced three new business partners. Lockheed Martin, Northrop Grumman and Draper will all have a hand in the process of making commercial space flight possible.

It was a busy week for another group of notable CEOs as well. Both Under Armour’s and Nike’s chief executives announced they would be leaving their respective roles in January, 2020.

Stay tuned for some eye-opening Halloween numbers as well!

Part of this channel

Draper

Real perspectives on quality and value in US manufacturing

Visit the channel →

About the author

Geoff Short

Turn this into your own content

Create a free MarketScale workspace and publish your own experts. No credit card, no demo required.

Book a demo Start free

MarketScale platform

Want to launch your own podcast or show?

MarketScale gives B2B companies a full content studio: record, produce, and distribute your own channel. No agency, no crew, no guessing.

See how it works →

Keep exploring

Executive Thought Leadership
Put researchers on the record.
State of GEO & AI Visibility
How B2B brands get cited by AI search.

sciences Events

Institute of Food Technologists Annual Meeting and Food Expo

Jul 19, 2026 · Chicago, IL

American Chemical Society National Meeting & Exposition

Aug 16, 2026 · Virtual

European Molecular Biology Organization Meeting

Oct 19, 2026 · Virtual

See all sciences events ›

Follow Sciences Insights

Get new expert content in your inbox.

Become an Industry Voice

Share your expertise with 1,250+ B2B brands on MarketScale.

Apply to participate

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Request info →Book a demo

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

Start free Book a demo

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace

One video edit a month, on us

AI writing, editing, and publishing tools

In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Geoff Short

Company

For Sciences teams

See how Sciences teams use MarketScale →

Executive Thought Leadership